Journal of Pharmacology and Experimental Therapeutics: 382 (2)

August 01, 2022; Volume 382,Issue 2

Minireview

You have access
Targets of Neuroprotection and Review of Pharmacological Interventions in Traumatic Brain Injury
Matthew I. Hiskens

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 149-166; DOI: https://doi.org/10.1124/jpet.121.001023

You have access
Effects of Daily Methocinnamox Treatment on Fentanyl Self-Administration in Rhesus Monkeys
David R. Maguire and Charles P. France

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 181-187; DOI: https://doi.org/10.1124/jpet.122.001233

You have access
Cyclosporine A Downregulates Selenoprotein P Expression via a Signal Transducer and Activator of Transcription 3–Forkhead Box Protein O1 Pathway in Hepatocytes In Vitro
Xingyu Yao, Hiroaki Takayama, Kyoko Kamoshita, Hein Ko Oo, Ryota Tanida, Kaisei Kato, Kiyo-Aki Ishii and Toshinari Takamura

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 199-207; DOI: https://doi.org/10.1124/jpet.121.001175

You have access
A Novel Sulindac Derivative Protects against Oxidative Damage by a Cyclooxygenase-Independent Mechanism
Shailaja Kesaraju Allani, Ramanjaneyulu Rayala, Oscar Rivera, Howard M. Prentice, Xi Chen, Verónica Ramírez-Alcántara, Joshua Canzoneri, Janet Menzie-Suderam, Xupei Huang, Constantin Georgescu, Jonathan D. Wren, Gary A. Piazza and Herbert Weissbach

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 79-87; DOI: https://doi.org/10.1124/jpet.122.001086
Open Access
Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy
Pierre-Axel Monternier, Parveen Parasar, Pierre Theurey, Pascale Gluais Dagorn, Navtej Kaur, Tavarekere N Nagaraja, Pascale Fouqueray, Sébastien Bolze, David E. Moller, Jaspreet Singh and Sophie Hallakou-Bozec

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 208-222; DOI: https://doi.org/10.1124/jpet.122.001208

You have access
The Nonpeptide Agonist MK-5046 Functions As an Allosteric Agonist for the Bombesin Receptor Subtype-3
Irene Ramos-Alvarez, Tatiana Iordanskaia, Samuel A. Mantey and Robert T. Jensen

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 66-78; DOI: https://doi.org/10.1124/jpet.121.001033
You have access
DR7dA, a Novel Antioxidant Peptide Analog, Demonstrates Antifibrotic Activity in Pulmonary Fibrosis In Vivo and In Vitro
Lu Cheng, Dan Wang, Bochuan Deng, Jieru Li, Jiao Zhang, Xiaomin Guo, Tiantian Yan, Xin Yue, Yingying An, Bangzhi Zhang and Junqiu Xie

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 100-112; DOI: https://doi.org/10.1124/jpet.121.001031
Open Access
8-Aminoinosine and 8-Aminohypoxanthine Inhibit Purine Nucleoside Phosphorylase and Exert Diuretic and Natriuretic Activity
Edwin K. Jackson, Elizabeth V. Menshikova, Vladimir B. Ritov, Zaichuan Mi and Lori A. Birder

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 135-148; DOI: https://doi.org/10.1124/jpet.122.001221
You have access
Thymidine Kinase 1 Mediates the Synergistic Antitumor Activity of Ubenimex and Celecoxib via Regulation of Cell Cycle in Colorectal Cancer
Aimin Wang, Yue Shang, Jun Ni, Wendie Wang, Chen Wang, Gaojie Li and Shu-zhen Chen

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 188-198; DOI: https://doi.org/10.1124/jpet.122.001118

You have access
Identification of Infigratinib as a Potent Reversible Inhibitor and Mechanism-Based Inactivator of CYP2J2: Nascent Evidence for a Potential In Vivo Metabolic Drug-Drug Interaction with Rivaroxaban
Lloyd Wei Tat Tang, Guoyi Wu and Eric Chun Yong Chan

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 123-134; DOI: https://doi.org/10.1124/jpet.122.001222
You have access
Zhx2 Is a Candidate Gene Underlying Oxymorphone Metabolite Brain Concentration Associated with State-Dependent Oxycodone Reward
Jacob A. Beierle, Emily J. Yao, Stanley I. Goldstein, William B. Lynch, Julia L. Scotellaro, Anyaa A. Shah, Katherine D. Sena, Alyssa L. Wong, Colton L. Linnertz, Olga Averin, David E. Moody, Christopher A. Reilly, Gary Peltz, Andrew Emili, Martin T. Ferris and Camron D. Bryant

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 167-180; DOI: https://doi.org/10.1124/jpet.122.001217

You have access
A Dopamine D₁ Agonist Versus Methylphenidate in Modulating Prefrontal Cortical Working Memory
Yang Yang, Mechelle M. Lewis, Lan Kong and Richard B. Mailman

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 88-99; DOI: https://doi.org/10.1124/jpet.122.001215
Open Access
Effects of the Glycine Transporter-1 Inhibitor Iclepertin (BI 425809) on Sensory Processing, Neural Network Function, and Cognition in Animal Models Related to Schizophrenia
Holger Rosenbrock, Cornelia Dorner-Ciossek, Riccardo Giovannini, Bernhard Schmid and Niklas Schuelert

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 223-232; DOI: https://doi.org/10.1124/jpet.121.001071

You have access
Nafamostat is a Potent Human Diamine Oxidase Inhibitor Possibly Augmenting Hypersensitivity Reactions during Nafamostat Administration
Thomas Boehm, Marion Alix, Karin Petroczi, Serhii Vakal, Elisabeth Gludovacz, Nicole Borth, Tiina A. Salminen and Bernd Jilma

Journal of Pharmacology and Experimental Therapeutics August 2022, 382 (2) 113-122; DOI: https://doi.org/10.1124/jpet.122.001248